TuesdayJan 14, 2025 8:45 am

BioMedNewsBreaks – PaxMedica Inc. (PXMD) Secures Patent Approval in China for Autism Treatment

PaxMedica (OTC: PXMD), a clinical-stage biopharmaceutical company focused on neurological disorders, has received a Notification to Grant Patent Right for its Chinese invention patent application (No: 2020800553323). The patent covers compositions and methods for treating cognitive, social, or behavioral disabilities and neurodevelopmental disorders, including autism, using a novel intranasal suramin formulation. CEO Howard Weisman highlighted this as a historic milestone, marking the first intellectual property protection for suramin in over a century. PaxMedica plans to pursue similar protections in additional jurisdictions, including the United States. To view the full press release, visit https://ibn.fm/DW1iE About PaxMedica Inc. PaxMedica is a forward-looking,…

Continue Reading

TuesdayJan 14, 2025 7:35 am

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Present Breakthrough Virotherapy Platform at AACR 2025

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company specializing in targeted antitumor virotherapies, announced its abstract, "Development of a Systemic Enveloped Virotherapy for Targeting All Metastatic Sites," has been accepted for presentation at the American Association for Cancer Research ("AACR") Annual Meeting, April 25-30, 2025, in Chicago. The presentation will highlight Calidi’s proprietary RTNova systemic platform, which leverages a novel vaccinia virus strain enveloped with a human cell membrane to overcome immune system elimination, enabling targeted delivery to multiple metastatic tumor sites. This innovative approach aims to address treatment challenges in advanced metastatic cancers, such as lung cancer, where…

Continue Reading

MondayJan 13, 2025 2:59 pm

BioMedNewsBreaks — Adageis’s Platform Empowering Organizations to Adjust to New Risk-Scoring Dynamics

Adageis, a forward-thinking healthcare technology company reshaping patient care through flexible AI-centric software solutions, is in support of the Centers for Medicare and Medicaid Services’ (“CMS”) switching from the V24 to the V28 upgrade of the Hierarchical Condition Categories (“HCC”) model. “The transition from CMS-HCC V24 to V28 reflects a critical update to the risk adjustment model used in Medicare Advantage… The more precise structure enhances diagnostic specificity, allowing for better patient categorization. This change supports value-based care by tying payments more closely to actual patient needs,” reads a recent article. “The CMS-HCC transition aligns closely with Adageis’s mission of…

Continue Reading

MondayJan 13, 2025 7:30 am

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Prices $4.25 Million Public Offering

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on targeted immunotherapies, has priced its public offering of 5,000,000 shares of common stock at $0.85 per share, with gross proceeds expected to total approximately $4.25 million before fees and expenses. The offering, exclusively placed by Ladenburg Thalmann & Co. Inc., is set to close on or around Jan. 10, 2025, subject to customary conditions. Proceeds will support working capital and general corporate purposes. The shares are offered under an effective Form S-3 registration statement, with a final prospectus available on the SEC’s website or through Ladenburg Thalmann. To view…

Continue Reading

FridayJan 10, 2025 9:41 am

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces Public Offering of Common Stock and Warrants

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on advanced immunotherapies, announced plans to offer shares of its common stock and/or pre-funded warrants in a public offering. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent. The offering's size and terms depend on market conditions and are yet to be finalized. Proceeds will support working capital and general corporate purposes. The securities will be offered under an effective shelf registration statement filed with the SEC, and interested parties can access the preliminary prospectus and accompanying documents via the SEC website or through Ladenburg Thalmann's Prospectus…

Continue Reading

WednesdayJan 08, 2025 2:29 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company recently secured a new $10 million debt facility, which enables the payoff of another higher interest rate loan and the finance of operations to generate additional data to support the new drug application of lead drug candidate CNM-Au8 for ALS. “We believe that the proceeds from this new debt facility, including an extended interest-only period, will allow Clene the cash…

Continue Reading

TuesdayJan 07, 2025 1:10 pm

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Streamlined Pathway to Advance Buntanetap for AD

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), today announced that the FDA has accepted an updated protocol for the pivotal Phase 3 AD study, which is slated to begin in January 2025. In October 2024, the FDA granted clearance for Annovis to proceed with the pivotal Phase 3 AD studies based on its Phase 2/3 data demonstrating cognitive improvement in early-stage AD patients. The original protocol design proposed two separate trials that are now integrated into a single 6/18-month trial under the…

Continue Reading

MondayJan 06, 2025 8:50 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Engage Investors and Partners at Key January Conferences

Scinai Immunotherapeutics (NASDAQ: SCNI) a biopharmaceutical company focused on inflammation and immunology products and CDMO services, announced CEO Amir Reichman and Chairman Mark Germain will participate in several high-profile events in January 2025. They will attend the IATI Mini Mixiii Conference in Miami on January 9, followed by the JP Morgan HealthCare Conference and SIC Biotech Symposium in San Francisco from January 13-15. The executives plan to meet with investors, potential pharmaceutical partners, and prospective CDMO clients to advance collaborations and highlight Scinai's innovative NanoAbs and biologics services. To view the full press release, visit https://ibn.fm/fkDUg About Scinai Immunotherapeutics Ltd.…

Continue Reading

FridayJan 03, 2025 2:36 pm

BioMedNewsBreaks — Adageis Is Reshaping Patient Care Through AI-Centric Approach

Adageis, a forward-thinking healthcare technology company, is ramping up patient care through flexible AI-centric software solutions for systems and providers, including accountable care organizations (“ACOs”), clinically integrated networks (“CINs”) and independent physician associations (“IPAs”). With a unique proposition in the space, the company is actively improving healthcare delivery and increasing value-based care revenue by streamlining operations via its ProActive Care Platform. “Integrating AI and machine learning, this easy-to-use platform works with existing electronic health records (‘HER’) systems and fits the needs of all current healthcare platforms, whether operated by providers owning a single clinic or a multispecialty healthcare system,” reads…

Continue Reading

FridayDec 27, 2024 1:49 pm

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Eyes Opportunities Beyond ‘Year of Significant Progress’

Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, was featured in a recent article that discussed the company’s year-end investor webcast, where it provided stakeholders with a comprehensive overview of 2024 milestones and strategic initiatives for 2025. The webcast also highlighted financial developments, including the securing of a $50 million At-The-Market (“ATM”) offering and ongoing strategic efforts to raise additional funds to support clinical trial development and long-term growth. “2024 has been a year of significant progress for Annovis Bio, and we are excited about the opportunities ahead,” Dr. Maria Maccecchini, founder, president…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000